Heart Failure With Preserved Ejection Fraction

Conclusions

AP in HFpEF patients with a history of coronary artery disease is common despite medical therapy and previous revascularization, and it is independently associated with increased MACE due to revascularization, with similar risk of death, MI, stroke, and hospitalization. Given the paucity of treatments for HFpEF patients, these data provide the foundation for pharmacological studies targeting anginal symptoms to reduce the morbidity associated with repeat revascularizations. Future prospective studies of angina in HFpEF patients are warranted.